Literature DB >> 9873795

Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group.

S Schulman1.   

Abstract

Continuous infusion with coagulation factor concentrates has only been widely adopted during the last decade and with recombinant activated factor VII (rFVIIa) only during the last 2 years. Still the accumulated number of days on continuous infusion with this product amounts by now to more than one year, 35 patients and 26 surgical procedures. The experience is reviewed here and compared with data from the conventional bolus dose regimen.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9873795     DOI: 10.1046/j.1365-2516.1998.440564.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

Review 2.  The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.

Authors:  Giancarlo Castaman
Journal:  Blood Transfus       Date:  2017-05-16       Impact factor: 3.443

3.  Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia.

Authors:  B T Yilmaz; B Alioglu; E Ozyurek; H T Akay; S Mercan; N Ozbek
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

4.  Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with congenital factor XI deficiency.

Authors:  Zekai Avci; Baris Malbora; Mahmut Gokdemir; Suleyman Ozkan; Namik Ozbek
Journal:  Pediatr Cardiol       Date:  2007-09-20       Impact factor: 1.655

Review 5.  Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency.

Authors:  Madhvi Rajpurkar; David L Cooper
Journal:  J Blood Med       Date:  2018-11-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.